SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Coradini Robert (Last) (First) (Middle) C/O WAFERGEN BIO-SYSTEMS, INC. 7400 PASEO PADRE PARKWAY (Street) FREMONT CA 94555 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol WaferGen Bio-systems, Inc. [ WGBS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/27/2013
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2013		A		70,218	A	(2)	73,382	D
Common Stock	08/27/2013		A		62,500	A	(5)	135,882	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-1 Convertible Preferred Stock	(1)(6)	08/27/2013		D			24,038.46	(1)	(1)	Common Stock	2,419	(2)	0	D
Common Stock Warrant (right to buy)	$61.62	08/27/2013		D			4,625	(3)	(3)	Common Stock	4,625	(2)	0	D
Convertible Promissory Note due 11/27/2014	$56.65	08/27/2013		D			$139,811	(4)	(4)	Common Stock	2,468	(2)	0	D
Common Stock Warrant (right to buy)	$2.6	08/27/2013		A		19,386		08/27/2013	08/27/2018	Common Stock	19,386	(2)	19,386	D
Common Stock Warrant (right to buy)	$2.6	08/27/2013		A		31,250		08/27/2013	08/27/2018	Common Stock	31,250	(5)	31,250	D

Explanation of Responses:

1. The securities were convertible into common stock at any time following their issuance on May 27, 2011, on a 9.939-for-1 basis, and had no expiration date.

2. The reporting person disposed of 24,038.46 shares of Series A-1 convertible preferred stock, 4,625 common stock warrants and a convertible promissory note with a principal amount of $139,811, including accrued interest, in exchange for 70,218 shares of common stock and 19,386 common stock warrants in an issuer exchange transaction.

3. The securities were convertible into common stock at any time following their issuance on May 27, 2011, until their expiry five years thereafter.

4. The principal amount of the security includes interest earned from their issuance on May 27, 2011, up until August 27, 2013, and was convertible into Series A-2 convertible preferred stock, in whole or in part, at any time following their issuance, from time to time, with no expiration date. Each share of Series A-2 convertible preferred stock was convertible into common stock at any time on a 9.939-for-1 basis, with no expiration date.

5. The reported securities are included within 2.5 Units acquired by the reporting person from the issuer in a private placement for $50,000 per Unit. Each Unit consists of twenty five thousand (25,000) shares of common stock and twelve thousand five hundred (12,500) warrants to purchase one share of common stock.

6. On August 27, 2013, the common stock of WaferGen Bio-systems, Inc. was subject to a 1-for-99.39 reverse split. All dispositions, acquisitions and conversion ratios are recorded on a post-split basis.

Remarks:

	/s/ Robert Coradini	08/29/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.